伐达司他在接受腹膜透析的透析依赖型慢性肾脏病患者中治疗贫血
INNO2VATE 两项随机开放标签Ⅲ期试验的事后分析纳入基线时接受腹膜透析的 309 例患者,比较伐达司他与达依泊汀α的心血管安全性和血红蛋白疗效。主要安全终点首次主要心血管事件风险两组相似(HR 1.10,95%CI 0.62–1.93),主要疗效终点血红蛋白平均变化差值为 -0.10 g/dL(95%CI -0.33–0.12)。
要点
- 腹膜透析亚组中伐达司他与达依泊汀α首次主要心血管事件风险相似。
- 主要评估期血红蛋白平均变化两组差值为 -0.10 g/dL(95%CI -0.33–0.12)。
- 治疗期间不良事件发生率伐达司他组 88.2%、达依泊汀α组 95.5%。
核心结论
- 在 INNO2VATE Ⅲ期试验的腹膜透析亚组中,伐达司他的安全性和疗效与达依泊汀α相似。
研究设计与样本
- 对两项随机(1:1)、全球、Ⅲ期、开放标签、申办方盲法、平行组、活性对照非劣效试验 INNO2VATE 中基线时接受腹膜透析的患者进行事后分析。
- 两项 INNO2VATE 试验共随机 3923 例患者,其中 309 例基线时接受腹膜透析(伐达司他组 n=152,达依泊汀α组 n=157)。
- 预设主要安全终点为首次主要心血管事件(MACE,定义为全因死亡或非致死性心肌梗死或卒中)时间。
- 主要疗效终点为基线至主要评估期(第 24–36 周)血红蛋白平均变化。
主要发现
- 首次 MACE 时间在伐达司他组与达依泊汀α组相似(HR 1.10;95%CI 0.62–1.93)。
- 腹膜透析患者主要评估期血红蛋白平均变化差值为 -0.10 g/dL(95%CI -0.33–0.12)。
- 治疗期间不良事件发生率伐达司他组 88.2% vs 达依泊汀α组 95.5%。
- 严重治疗期间不良事件发生率伐达司他组 52.6% vs 达依泊汀α组 73.2%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hypoxia-inducible factor prolyl hydroxylase inhibitors such as vadadustat may provide an oral alternative to injectable erythropoiesis-stimulating agents for treating anemia in patients receiving peritoneal dialysis. In two randomized (1:1), global, phase 3, open-label, sponsor-blind, parallel-group, active-controlled noninferiority trials in patients with dialysis-dependent chronic kidney disease (INNO2VATE), vadadustat was noninferior to darbepoetin alfa with respect to cardiovascular safety and hematological efficacy. Vadadustat's effects in patients receiving only peritoneal dialysis is unclear. METHODS: We conducted a post hoc analysis of patients in the INNO2VATE trials receiving peritoneal dialysis at baseline. The prespecified primary safety endpoint was time to first major cardiovascular event (MACE; defined as all-cause mortality or nonfatal myocardial infarction or stroke). The primary efficacy endpoint was mean change in hemoglobin from baseline to the primary evaluation period (Weeks 24-36). RESULTS: Of the 3923 patients randomized in the two INNO2VATE trials, 309 were receiving peritoneal dialysis (vadadustat, n = 152; darbepoetin alfa, n = 157) at baseline. Time to first MACE was similar in the vadadustat and darbepoetin alfa groups [hazard ratio 1.10; 95% confidence interval (CI) 0.62, 1.93]. In patients receiving peritoneal dialysis, the difference in mean change in hemoglobin concentrations was -0.10 g/dL (95% CI -0.33, 0.12) in the primary evaluation period. The incidence of treatment-emergent adverse events (TEAEs) was 88.2% versus 95.5%, and serious TEAEs was 52.6% versus 73.2% in the vadadustat and darbepoetin alfa groups, respectively. CONCLUSIONS: In the subgroup of patients receiving peritoneal dialysis in the phase 3 INNO2VATE trials, safety and efficacy of vadadustat were similar to darbepoetin alfa.
引用
- Sarnak MJ, Agarwal R, Boudville N, et al. Vadadustat for treatment of anemia in patients with dialysis-dependent chronic kidney disease receiving peritoneal dialysis. Nephrol Dial Transplant. 2023. PMID: 37096396. doi:10.1093/ndt/gfad074
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。